Literature DB >> 11483738

Mutations in the fusion peptide and adjacent heptad repeat inhibit folding or activity of the Newcastle disease virus fusion protein.

T A Sergel1, L W McGinnes, T G Morrison.   

Abstract

Paramyxovirus fusion proteins have two heptad repeat domains, HR1 and HR2, which have been implicated in the fusion activity of the protein. Peptides with sequences from these two domains form a six-stranded coiled coil, with the HR1 sequences forming a central trimer (K. A. Baker, R. E. Dutch, R. A. Lamb, and T. S. Jardetzky, Mol. Cell 3:309-319, 1999; X. Zhao, M. Singh, V. N. Malashkevich, and P. S. Kim, Proc. Natl. Acad. Sci. USA 97:14172-14177, 2000). We have extended our previous mutational analysis of the HR1 domain of the Newcastle disease virus fusion protein, focusing on the role of the amino acids forming the hydrophobic core of the trimer, amino acids in the "a" and "d" positions of the helix from amino acids 123 to 182. Both conservative and nonconservative point mutations were characterized for their effects on synthesis, stability, proteolytic cleavage, and surface expression. Mutant proteins expressed on the cell surface were characterized for fusion activity by measuring syncytium formation, content mixing, and lipid mixing. We found that all mutations in the "a" position interfered with proteolytic cleavage and surface expression of the protein, implicating the HR1 domain in the folding of the F protein. However, mutation of five of seven "d" position residues had little or no effect on surface expression but, with one exception at residue 175, did interfere to various extents with the fusion activity of the protein. One of these "d" mutations, at position 154, interfered with proteolytic cleavage, while the rest of the mutants were cleaved normally. That most "d" position residues do affect fusion activity argues that a stable HR1 trimer is required for formation of the six-stranded coiled coil and, therefore, optimal fusion activity. That most of the "d" position mutations do not block folding suggests that formation of the core trimer may not be required for folding of the prefusion form of the protein. We also found that mutations within the fusion peptide, at residue 128, can interfere with folding of the protein, implicating this region in folding of the molecule. No characterized mutation enhanced fusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483738      PMCID: PMC115037          DOI: 10.1128/jvi.75.17.7934-7943.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  The role of position a in determining the stability and oligomerization state of alpha-helical coiled coils: 20 amino acid stability coefficients in the hydrophobic core of proteins.

Authors:  K Wagschal; B Tripet; P Lavigne; C Mant; R S Hodges
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion.

Authors:  L Chen; J J Gorman; J McKimm-Breschkin; L J Lawrence; P A Tulloch; B J Smith; P M Colman; M C Lawrence
Journal:  Structure       Date:  2001-03-07       Impact factor: 5.006

3.  The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil.

Authors:  J M Matthews; T F Young; S P Tucker; J P Mackay
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Effects of side-chain characteristics on stability and oligomerization state of a de novo-designed model coiled-coil: 20 amino acid substitutions in position "d".

Authors:  B Tripet; K Wagschal; P Lavigne; C T Mant; R S Hodges
Journal:  J Mol Biol       Date:  2000-07-07       Impact factor: 5.469

5.  Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex.

Authors:  M K Lawless-Delmedico; P Sista; R Sen; N C Moore; J B Antczak; J M White; R J Greene; K C Leanza; T J Matthews; D M Lambert
Journal:  Biochemistry       Date:  2000-09-26       Impact factor: 3.162

6.  Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins.

Authors:  P Chambers; C R Pringle; A J Easton
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

7.  Structural characterization of the human respiratory syncytial virus fusion protein core.

Authors:  X Zhao; M Singh; V N Malashkevich; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

8.  Activation of the Sendai virus fusion protein (f) involves a conformational change with exposure of a new hydrophobic region.

Authors:  M Hsu; A Scheid; P W Choppin
Journal:  J Biol Chem       Date:  1981-04-10       Impact factor: 5.157

9.  Carbohydrate modifications of the NDV fusion protein heptad repeat domains influence maturation and fusion activity.

Authors:  L McGinnes; T Sergel; J Reitter; T Morrison
Journal:  Virology       Date:  2001-05-10       Impact factor: 3.616

10.  A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses.

Authors:  D Rapaport; M Ovadia; Y Shai
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

View more
  22 in total

1.  The transmembrane domain sequence affects the structure and function of the Newcastle disease virus fusion protein.

Authors:  Kathryn A Gravel; Lori W McGinnes; Julie Reitter; Trudy G Morrison
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein.

Authors:  Laura E Luque; Charles J Russell
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Role of the simian virus 5 fusion protein N-terminal coiled-coil domain in folding and promotion of membrane fusion.

Authors:  Dava S West; Michael S Sheehan; Patrick K Segeleon; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Newcastle disease virus HN protein alters the conformation of the F protein at cell surfaces.

Authors:  Lori W McGinnes; Kathryn Gravel; Trudy G Morrison
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Examination of a fusogenic hexameric core from human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptad repeat 1 region.

Authors:  Scott A Miller; Sharon Tollefson; James E Crowe; John V Williams; David W Wright
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

6.  Interacting domains of the HN and F proteins of newcastle disease virus.

Authors:  Kathryn A Gravel; Trudy G Morrison
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Mutations in the ectodomain of newcastle disease virus fusion protein confer a hemagglutinin-neuraminidase-independent phenotype.

Authors:  Juan Ayllón; Enrique Villar; Isabel Muñoz-Barroso
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Nucleotide and predicted amino acid sequence analysis of the fusion protein and hemagglutinin-neuraminidase protein genes among Newcastle disease virus isolates. Phylogenetic relationships among the Paramyxovirinae based on attachment glycoprotein sequences.

Authors:  Bruce S Seal
Journal:  Funct Integr Genomics       Date:  2004-04-24       Impact factor: 3.410

9.  Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Authors:  Abdul S Yunus; Trent P Jackson; Katherine Crisafi; Irina Burimski; Nicole R Kilgore; Dorian Zoumplis; Graham P Allaway; Carl T Wild; Karl Salzwedel
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

10.  Conserved leucines in N-terminal heptad repeat HR1 of envelope fusion protein F of group II nucleopolyhedroviruses are important for correct processing and essential for fusogenicity.

Authors:  Gang Long; Xiaoyu Pan; Just M Vlak
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.